Group 1: Positive Factors - The advancement of Sino-U.S. regulatory cooperation has alleviated the delisting risks for Chinese companies listed in the U.S. [2] - The Federal Reserve's interest rate cuts in 2024 are expected to enhance market liquidity, leading to a projected 116% year-on-year increase in fundraising for Chinese companies going public in the U.S. [3] - Specific industries such as biomedicine and hard technology are likely to benefit from U.S. market valuations that recognize innovation and high R&D investments [4] - The internationalization demand in sectors like new energy and autonomous driving has led to significant brand effects for companies like Zeekr and WeRide after their U.S. listings [5] - The U.S. has a more accommodating stance towards cryptocurrency companies, attracting Chinese firms to split their businesses and list in the U.S. [6] - New policies in China support the expansion of overseas listing channels, with the China Securities Regulatory Commission (CSRC) optimizing the filing process, resulting in a significant increase in the number of companies preparing for listings in 2024 [7] Group 2: Major Challenges - Geopolitical tensions and regulatory conflicts remain a concern, particularly with the U.S. Foreign Company Accountability Act posing potential delisting risks if Sino-U.S. audit cooperation falters [8] - Compliance pressures from China's Data Security Law require companies to separate sensitive operations or localize data storage, increasing listing costs [9] - Market performance is uneven, with over two-thirds of Chinese companies listed in the U.S. in 2024 experiencing stock price declines, while smaller firms face high issuance costs that diminish fundraising efficiency [10] - The Hong Kong Stock Exchange has lowered listing thresholds for specialized technology companies, creating competition for Chinese firms considering dual listings [11] - The A-share Sci-Tech Innovation Board is prioritizing hard technology companies, which may lead to local financing preferences [12] - Nasdaq's new rules set to be implemented by the end of 2024 will increase the difficulty for small and medium-sized enterprises to meet market capitalization requirements for IPOs [13] Group 3: Future Outlook - An optimistic scenario suggests that if Sino-U.S. regulatory cooperation deepens and the Federal Reserve continues to lower interest rates, leading tech and biomedicine companies could see a 20%-30% year-on-year increase in IPO fundraising [14][15] - A neutral scenario indicates that if regulatory deadlocks persist but geopolitical tensions remain manageable, a few companies may pursue dual listings or split non-sensitive operations for U.S. entry, resulting in moderate fundraising growth [16][17] - A pessimistic scenario predicts that if the Sino-U.S. tech conflict escalates and China tightens overseas listing approvals, IPO activities in the U.S. could nearly halt, accelerating the privatization of existing Chinese companies listed abroad [18][19] Group 4: Corporate Strategy Recommendations - Companies are advised to prioritize compliance by designing cross-border data and legal frameworks, such as VIE structures and independent data entities [20] - Diversifying financing strategies through a combination of A-share/H-share and U.S. listings can help mitigate risks [21] - Companies in hard technology should focus on local listings, while those with strong global attributes, like biomedicine, should target U.S. markets [22]